2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice


ABSTRACT

Background Non-adherence to treatment could preclude reaching an optimal outcome. Thirty to 80% of patients with rheumatic and musculoskeletal diseases (RMDs) do not adhere to the agreed treatment.

Objectives The objective was to establish points to consider (PtCs) for the prevention, screening, assessment and management of non-adherence to (non-)pharmaceutical treatments in people with RMDs.

Methods An EULAR task force (TF) was established, and the EULAR standardised operating procedures for the development of PtCs were followed. The TF included healthcare providers (HCPs), comprising rheumatologists, nurses, pharmacists, psychologists, physiotherapists, occupational therapists and patient-representatives from 12 European countries. A review of systematic reviews was conducted in advance to support the TF in formulating the PtCs. The level of agreement among the TF was established by anonymous online voting.

Results Four overarching principles and nine PtCs were formulated. The PtCs reflect the phases of action on non-adherence. HCPs should assess and discuss adherence with patients on a regular basis and support patients to treatment adherence. As adherence is an agreed behaviour, the treatment has to be tailored to the patients’ needs. The level of agreement ranged from 9.5 to 9.9 out of 10.

Conclusions These PtCs can help HCPs to support people with RMDs to be more adherent to the agreed treatment plan. The basic scheme being prevent non-adherence by bonding with the patient and building trust, overcoming structural barriers, assessing in a blame-free environment and tailoring the solution to the problem.

INTRODUCTION

Thirty to 80% of people with rheumatic and musculoskeletal diseases (RMDs) do not follow the recommended treatment plan.1–3 Non-adherence equally affect medication, non-pharmacological interventions and keeping follow-up appointments and are associated with worse outcomes, increased risk of cardiovascular disease, decreased functioning and loss of health-related quality of life.1–7 Strategies to reduce non-adherence are thus essential to achieve an optimal outcome.4–6

The problem of non-adherence is addressed in some EULAR recommendations on the management of specific health conditions or in the role of professionals, but none specifies interventions in or actual directions on how to improve non-adherent behaviour.8–11 All these recommendations focus on specific aspects of non-adherence and do not cover the multifaceted nature of this phenomenon, such as its detection or assessment.

Although general recommendations are lacking, a large number of studies have tested various interventions targeting non-adherence, including screening and assessment of non-adherence,1 provision of equitable and coordinated access to treatment through, for example, flexibility in scheduling or financial resources according to the respective health system,12 integration of patients in treatment decisions,13,14 enhancement of patients’ autonomy,11 stratification and individualisation of interventions based on the needs and preferences of patients including psychosocial markers,8,9 information and education,10–13 systems to remind patients about appointments, intake of medication and exercises whenever necessary,14 compatibility of treatment interventions to the daily routines of patients,9,13 and offer opportunities to get in touch with other individuals with similar health conditions or other social support.12,13 Interventions are delivered by rheumatologists, other medical specialists, general practitioners or health professionals in rheumatology (HPRs) (ie, nurses, pharmacists, physiotherapists, occupational therapists and psychologists) in close collaboration with each other in primary and secondary care settings.

The objective of the present work is to establish points to consider (PtCs) for the prevention, screening, assessment and management of non-adherence in people with RMDs for use in daily clinical practice.

The users of these PtCs are intended to be rheumatologists and HPRs (together will be referred as
healthcare providers or HCPs), patients and caregivers, regulators, trainers and others, at the individual or organisational level (eg, patient organisations, pharmaceutical and/or insurance companies). Regarding their scope, these PtCs are applicable to all RMDs, except those with an acute or subacute course (eg, some viral arthritis), as longer duration of diseases increase the chances of non-adherence.13 In addition, the scope of the PtCs does not include children and adolescents, as their non-adherent behaviour differs from that of adults, mainly on its great reliance on social support of caregivers.15 We acknowledge that different RMDs may have specific problems—for example, non-symptomatic conditions, such as osteoporosis, pose additional challenges to motivate a patient to follow a long-term prescription (prescription in this context refers to any instruction (mostly written) from a physician or health professional in rheumatology stating the form, dosage and kind of treatment, including but not limited to medications, exercises, diets and follow-up appointments); however, non-adherence affects them all, and only very exceptionally a PtC for an RMD might not apply to another.

In addition, these PtCs only refer to non-adherence to pharmacological or non-pharmacological treatments that are prescribed or recommended. They are not including non-adherence to lifestyle changes, such as diet, weight loss and smoking or to visit schedules. Regarding medication, the task force decided that symptomatic medicines may not be the specific objective of these PtCs, and that non-pharmacological treatments should be restricted to exercises and medical devices (eg, splints). Exercises may be defined as a type of physical activity that is planned, structured and purposeful.16 17

Finally, in the context of these PtCs and following the definition of the WHO, non-adherence is defined as the extent to which a person’s behaviour does not correspond with the agreed prescription, of pharmacological or non-pharmacological treatments, by an HCP.3 Besides being intentional or non-intentional, non-adherence (1) may occur at the start of treatment (initial non-acceptance), and so the patient never collects the prescription, or does not sign up to exercises, and hence does not follow any of the prescription; (2) may be a result of a poor execution, either by taking an incorrect dose, taking the drug at a wrong time or by decreasing or increasing the frequency of doses (or their equivalents in exercises or the use of medical devices) or (3) may be due to discontinuation of the treatment at any time during the treatment course.1

METHODS
These PtCs were developed according to the consensus process suggested by the EULAR Standard Operating Procedures.18 An international expert task force was established by a steering committee (LC, VR, AdT and TAS), and included people with RMDs (n=2), EMEUNET members (n=3 (AM, RGD and VR)), and representatives from relevant HCP groups: nurses (n=3), occupational therapists (n=2), psychologists (n=3), physiotherapists (n=1), pharmacists (n=2) and rheumatologists (n=6), all of whom had various levels of expertise in the field of non-adherence and came from a broad geographical distribution across Europe. A systematic review (SR) of reviews and meta-analysis on existing strategies to prevent or mitigate non-adherence, supervised by the methodologist and the convenors, was presented at a first task force meeting (the SR is subject of a separate publication19). In this meeting, the scope, users, structure of the document and overarching principles were established by nominal group technique, as well as additional clinical questions to be addressed by SR. These clinical questions were converted into Population Intervention Comparison Outcome questions by the convenors (LC and VR), methodologist (AdT) and research fellows (VR and JBN), and the search strategies developed, by an experienced Librarian, in Medline, CINAHL, web of science, science direct and the Cochrane Database of SR. The quality of the selected reviews was assessed using ‘A MeaSurement Tool to Assess systematic Reviews’ (available at https://amstar.ca/).

The quality and risk of bias of the original studies were obtained directly from the published reviews (ie, Cochrane Risk of Bias tool20 for intervention studies and QUADAS-221 for assessment studies). Because of the high heterogeneity, the evidence was synthesised qualitatively. In a second meeting of the task force, the results of the SR were discussed and the PtCs were formulated. Data from the SR were categorised according to the Oxford system for levels of evidence,22 and statements were voted and discussed using a three round Delphi technique. Level of agreement (LoA)/voting was scored anonymously (www.slid.do) on a numerical rating scale ranging from zero (completely disagree) to 10 (completely agree). The first two Delphi rounds were performed during the second task force meeting. Agreement in the Delphi was defined as >80% of experts within the task force voting in favour (nine or 10) or against (one or two) an item. Items with agreement against were excluded from the list. Items with agreement in favour were maintained without further voting, unless reformulation was proposed. All intermediate items and those that needed reformulation were voted in a second round. Finally, in the third Delphi round (done by electronic communication (www.surveymonkey.de)), task force members were asked to give their final rating on every point to consider. All members of the task force were asked to respond during each round.

RESULTS
The results of the taskforce efforts are divided into four overarching principles and nine PtCs. The difference, in absence of strong evidence, is that overarching principles are not suggestions on what to do, but more principles to understand why and how the following points are formulated. They are explained and justified in detail below and presented in table 1 with the accompanying level of evidence (LoE), grade of recommendation (GR) and LoA.22

Overarching principles
Overarching principle A: adherence impacts the outcomes of people with RMDs
In RMDs, non-adherence has been associated with worse disease severity, increased pain and fatigue, higher rates of depression, lower function and a decrease in quality of life and physical activity.19

Overarching principle B: shared decision making is key, since adherence is a behaviour following an agreed prescription
Ideally, patients and their HCPs should agree on the recommended treatment, including duration, dosage and frequency of medication intake, or exercises or device use over a period of time. To make an informed decision, patients need to understand their choices (ie, shared decision making, or SDM). The SDM process has been defined as ‘an approach where HCPs and patients share the best available evidence when faced with the task of making decisions, and where patients are supported to consider options, to achieve informed preferences’.22 During the SDM process, mutual expectations in terms of efficacy, safety and monitoring should be discussed, as well as fears and
necessities about the specific treatment. The patient should be informed about the need to be adherent and how adherence will be evaluated. Agreement is part of the definition of adherence in the sense that if the patient did not agree to start with, it could not be considered non-adherence. Although, SDM is ambitious in systems with time constraints and low availability of professionals, it cannot be overlooked if we want to action at all on non-adherence.

Overarching principle C: adherence is influenced by multiple factors
Patients may have comorbidities, multiple treatments, circumstances, cognitions and preferences that need to be taken into account, when addressing non-adherence. Health systems are complex and, in each setting, different HCPs may have different roles. These PtCs have an integrative approach that goes beyond the clinical encounter, as they stress that all, HCPs and patients, are involved in the care of patients.

Overarching principle D: adherence is a dynamic process that requires continuous evaluation
Patients’ beliefs and fears about prescribed treatments, as well as behaviours, are influenced by experience and by external and internal determinants, for example, depression, other comorbidities, side effects, lack of efficacy or life changes that pose logistic hurdles. We cannot assume that a person will continue to be adherent or non-adherent to any given treatment, and that this will be maintained and stable across prescriptions.

Points to consider
PtC 1: all HCPs involved in the management of people with RMDs should take responsibility for promoting adherence
Effective interventions to reduce non-adherence in RMDs were reviewed by our group, and we confirmed that HCP, both physicians—namely, rheumatologists, GP and orthopaedic surgeons—and HPRs—such as nurses, physiotherapists, occupational therapists, psychologists, exercise physiologists, patient educators and pharmacists—were involved in the delivery of these interventions.19 Nieuwlaat et al underscore in their Cochrane review that nurses, pharmacists and therapists are increasingly becoming part of delivering interventions that target non-adherent behaviour in people with RMDs.24 This PtC gives responsibility to the full care team. It highlights both the relevant role of these HPRs and also both the need to acknowledge their efforts, and to coordinate teams beyond the rheumatology clinic. Training in specific interventions—for example, motivational interview or communication skills—may also be behind effective or non-effective interventions.24 Very importantly, the HCPs should be involved and should be trained as well.

PtC 2: effective patient-health professional communication should be applied to enhance adherence
An overview of SR on strategies proven effective to reduce non-adherence to medication and prescribed exercises found that effective communication was part of most multifaceted interventions proven successful. Unfortunately, the content and nature of effective communication is not well detailed.19 Despite the absence of consensus on a definition of effective communication, its components—namely, empathy, open questions or bilateral feedback, among others—were discussed and detailed by the task force (see online supplemental table S3).25–27 Very importantly, as effective communication helps build trust with the patient and ensures a proper transmission of information about the condition and treatment,25–27 it should be in place before the point at which the prescription is discussed.

PtC 3: barriers and facilitators of adherence of a specific patient to a specific prescription should be appropriately evaluated
Many different factors determining non-adherent behaviour in people with RMDs have been identified in many studies, covering various domains. The WHO generated a framework by which these factors were classified into five different domains: (i) patient-related, (ii) condition-related, (iii) therapy-related, (iv) the socioeconomic context and (v) the healthcare system.1 Our overview of SR of qualitative studies demonstrated that the list of barriers and facilitators is extensive, with many factors not being modifiable, and none of them being a sole predictor of non-adherence.19

---

Table 1  Overarching principles and points to consider for the prevention, screening, assessment and management of non-adherence in people with RMDs for use in the daily clinical practice

<table>
<thead>
<tr>
<th>Overarching principles</th>
<th>LoE</th>
<th>GR</th>
<th>LoA</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Adherence impacts the outcomes of people with RMDs.</td>
<td>5</td>
<td>D</td>
<td>98.6</td>
</tr>
<tr>
<td>B Shared decision making is key, since adherence is a behaviour following an agreed prescription.</td>
<td>5</td>
<td>D</td>
<td>95.8</td>
</tr>
<tr>
<td>C Adherence is influenced by multiple factors.</td>
<td>5</td>
<td>D</td>
<td>97.5</td>
</tr>
<tr>
<td>D Adherence is a dynamic process that requires continuous evaluation.</td>
<td>5</td>
<td>D</td>
<td>96.2</td>
</tr>
</tbody>
</table>

Points to consider

1. All HCPs involved in the management of people with RMDs should take responsibility for promoting adherence.
2. Effective patient-health professional communication should be applied to enhance adherence.
3. Barriers and facilitators of adherence of a specific patient to a specific prescription should be appropriately evaluated.
4. Patient education should be provided for people with RMDs as an integral part of standard care.
5. Care should be tailored to patient preferences and goals to enhance adherence.
6. Adherence should be discussed regularly based on open questions and particularly when disease is not well controlled.
7. The HCP should explore which factors might negatively influence adherence, including: opportunity (eg, availability or cost), capability (eg, memory problems), motivation (eg, concerns).
8. Together with the patient, the HCP should tailor the approach to overcome individual barriers to adherence, for example, simplifying the regimen, using reminders, providing education, discussing the patient’s beliefs on treatments.
9. When specific expertise or interventions for adherence are needed, they should be made available to patients.

*Prescription in this context refers to any instruction (mostly written) from a physician or health professional in rheumatology stating the form, dosage and kind of treatment, including but not limited to medications, exercises, diets and follow-up appointments.

GR, grade of recommendation; HCP, healthcare providers; LoA, Level of agreement of task force members on a numeric rating scale from 0 (no agreement) to 10 (perfect agreement); LoE, level of evidence; RMDs, rheumatic and musculoskeletal diseases.
Some factors change with time and can appear either to be a cause, or a consequence, of patient non-adherence (eg, depression can lead to less motivation to adhere, but it can also be a consequence of disease activity due to non-adherence). Barriers to adherence are considered complex and multi-faceted and non-adherence should never be perceived as patients’ fault only (eg, the hospital pharmacy was not open the only day a patient could take off from work that month, or the patient’s skills for self-injection are very limited). Based on the overview SR, we have produced a checklist of factors related to non-adherence, which could help HCPs to identify barriers to adherence at the individual level (see online supplemental table S1).

PtC 4: patient education should be provided for people with RMDs as an integral part of standard care

Most interventions with proven effectiveness in non-adherence include components of patient education, namely provision of knowledge or information, self-management programmes, cognitive behavioural interventions, mindfulness, stress management, individual consultations, sharing experiences among patients, motivational discussions, exercise counselling, lifestyle change interventions and self-help courses. With this PtC, the task force wants to emphasise that ‘all people with RMDs should have access to and be offered patient education throughout the course of their disease including as a minimum; at diagnosis, at pharmacological treatment change and when required by the patient’s physical or psychological condition’. Of course, we cannot overwhelm the patient at diagnosis or treatment start with information, but studies agree in that patient education, either direct or supported via websites, brochures, SMS or e-health may reduce non-adherent behaviour. In order to be effective, education/information should include information about drugs, disease process, physical exercises, joint protection, pain control, coping strategies and lifestyle changes. Delivery formats can include verbally (face to face or by telephone), written (as leaflets or using test messages) and visualised in charts (see online supplemental table S2).

PtC 5: care should be tailored to patient preferences and goals to enhance adherence

As already mentioned, the list of potential factors that can influence non-adherence to treatment is extensive and challenging to address. However, building a trust and a sound patient–HCPs relationship will prepare the scene for a responsible and blame-free framework that will reduce non-adherence in the long term. This tailored care has a maximum exponent during the SDM process, when options and patient preferences are the basis for an agreement to be treated and monitored.

PtC 6: adherence should be discussed regularly based on open questions and particularly when disease is not well controlled

As adherence changes with time, the task force could not specify a best moment to assess non-adherence. Finally, we suggest that non-adherence should be assessed in a continuum. The task force discussed the opportunity to discuss non-adherence when the disease is not well controlled but specifically agreed to high-light the need for regularity. Regularly in this context would be, at a minimum, once per year.

Some experts within the TF argued to use validated measures of non-adherence, for instance, by the Medication Event Monitoring System, the level/dose ratio or the medication possession ratio. The reality is that the non-adherence construct has many grey areas and more than 200 ways to measure non-adherence to medication exist. The TF undertook an SR of instruments to screen non-adherence to medication and exercises in people with RMDs, including but not limited to validated questions, questionnaires, assessment and others (eg, pill counts, worn splint), without identifying a single measure that was clearly superior, neither for medication nor for exercises.

In practical terms, whether non-adherence is a problem or not, it should be discussed through open conversation with the patient. The ‘some people’ approach may facilitate the generation of a safe space for more elaborated questions and answers (“We know it can be difficult, everybody has some problems, could you tell me what problems you encountered when taking your medication?” or ‘Could you show me how you actually wear the splint? How do you actually perform the exercises?’). Other forms of screening, like questionnaires, looking at pharmacy indicators, drug levels or wearables can be used, always tailored to patient preferences and goals to reduce non-adherence, but a single measure without the open discussion is not recommended.

PtC 7: the HCP should explore which factors might negatively influence adherence, including opportunity (eg, availability or cost), capability (eg, memory problems) or motivation (eg, concerns)

This PtC adds a method or systematic approach to explore barriers to adherent behaviour. We used the Capability, Opportunity and Motivation model of Behaviour (COM-B) as framework to explore patient’s drivers for non-adherence and as instrument to identify possible targets for reducing non-adherence. The model acknowledges that behaviour is part of an interacting, dynamic system involving these components to determine a person’s non-adherence. The problems that are easiest to address are those of practical nature—for example, unavailability at local pharmacy, pharmacy open hours, interference with occupation —and thus they should be the first ones explored. Next would be knowledge or capability related, for example, the patient does not really understand the duration of treatment, what to do in case of missing dose, or how to inject. These can be explored by asking the patient, with some level of detail, how she or he actually takes the medication or, in the case of exercises, how he or she performs the exercises. Regardless of problems in these previous areas, the motivation to adhere, or intention, has to be explored. This is usually explored in terms of needs and concerns.

PtC 8: together with the patient, the HCP should tailor the approach to overcome individual barriers to adherence, for example, simplifying the regimen, using reminders, providing education, discussing the patient’s beliefs on treatments

Based on the reasons for non-adherence, the solutions must be tailored to tackle the specific problems. There is not general recipe or ‘one size fits all’ as how to do this and solutions to tackle non-adherence are plenty. The two steps of a tailored approach would be (1) to identify the reasons of non-adherence, including the assessment of problems, as well as low health literacy or skills, and (2) to focus on the specific problems, modulating the intervention to the individual (eg, a patient clearly needs a reminder but does not have a smartphone, we should recommend the use of pill boxes with timers). Some randomised controlled trials that specifically named their strategies as ‘tailored’ showed positive results. Many include revising treatment schemes to make them as convenient and easy to follow as possible.

Besides patient education strategies, already highlighted, there are simple things that can be done, like advising on cueing...
behaviours (eg, pairing medication taking with an established behaviour, such as brushing teeth), monitoring (eg, using a calendar or a diary to track medication taking), including the family and close ones in the intervention, reviewing plans/strategies and give feedback (including positive reinforcement) and answers. Individualising the prescription and regimen according to the preferences and goals of the patient has been proven effective. In the case of exercises, it has been suggested to split treatment visits, increase proxy efficacy (ie, patients’ confidence in the therapist’s ability to function effectively on his/her behalf; this can be done by showing that the therapist competency really aids achieving goals) and discuss barriers and facilitators of exercises with the patient, encouraging him/her to plan own treatment regimens, discussing intentions and helping recasting unrealistic plans, individualising physical activity advice, tailoring graded exercise programme, training in the proper execution of physical exercises and providing visual media of the prescribed exercises and explanatory written information. A list of practical things is shown in the online supplemental table S2.

**PtC 9: when specific expertise or interventions for adherence are needed, they should be made available to patients**

Some interventions, especially those related to avoid intentional non-adherence may need specialised skills, such as motivational interviewing. If the care team includes a psychologist, she or he should be ideally involved, either in the management of the individual patients or as trainer or consultant for the team members. Other skills, such as being able to deliver effective communication, are insufficiently incorporated in most teams.

### DISCUSSION

The topic of non-adherence is of utmost importance and yet not adequately addressed in rheumatology. Non-adherence both results in poorer outcomes and also in increased resource use and medical costs. Non-adherence varies across RMDs, being critical in gout, osteoporosis, but also in rheumatoid arthritis, where it even vary across medication. The work of this multidisciplinary taskforce has highlighted both the complexity and a possible practical approach to non-adherence to prescribed treatments in RMDs.

The WHO definition of adherence does not easily translate into operational terms, as it relates to a behaviour. Non-adherence can take many different forms: the patient could actually be overdosing the medication, the exercises or the use of devices, or not using it as prescribed (eg, misapplying medication or exercises, or using splints ineffectively). The complexity and difficulty of identifying factors accurately and predicting medication non-adherence has led to the development of cognitive models to better explain this complex phenomenon. These models take into account areas such as illness beliefs, expectations, barriers and intentions, and have become the basis of measurement instruments. In practical terms, and in the context of a frank discussion, we should ask the patient about his or her beliefs and concerns about treatments, as these are universally present in patients on long-term treatments. In this line, Foot et al found a moderate effect of pharmacological treatment necessity in rheumatoid arthritis and systemic sclerosis—both being the RMDs with largest ‘need’ belief of treatment—and lowest in osteoporosis, while they found a strong negative association between concerns about adverse effects of taking medicines and non-adherence in rheumatoid arthritis and in osteoporosis and moderate in systemic sclerosis. Patients will always weigh up necessity and concern, and therefore we have a ‘window of opportunity’ for patient education and counselling.

Patient-centered and shared decisions are key elements in relation to (non-)adherence. If perspectives and preferences of patients are not adequately taken into account in medical decisions, non-adherence might get a paternalistic connation. Instead the HCP ‘telling’ the patient what to do and the patient needing to follow this advice, a common patient-centric perspective should be established, and patients should be encouraged to take active role in the subsequent decision. However, we acknowledge, that it is not possible for HCPs to assess or be certain that a patient has agreed to the proposed treatment plan, especially because some patients may give socially desirable answers (for fear of disappointing the HCPs). Therefore, adherence should be discussed regularly, and the patients must be given assurance that they can be honest, because it is their right not to take the treatment as prescribed. However, the patients should also be encouraged to tell the HCPs about not taking the treatment as only with mutual trust, optimal can take place.

The aim of our taskforce was to be as practical as possible. Other groups have already issued recommendations to reduce non-adherence in RMDs, but they dealt specifically with medication and rheumatoid arthritis, and we wanted to be broader. A practical local initiative designed a model for prescription to tackle non-adherence, and in a very practical paper, Rashid et al synthesise the implications of qualitative research in the field of non-adherence into the following 11 statements: (1) individualise care plan, (2) address practical barriers for the individual, (3) adopt a patient-centred approach, (4) increase HCPs involvement, (5) ensure long-term follow-up, (6) promote self-management, (7) increase family or carer involvement, (8) improve patient education, (9) address system barriers, (10) increase access to non-prescribing HCPs and (11) improve staff training. Many of these suggestions reflect our views and conclusions.

Exercises are a pillar in the treatment of most RMDs and non-adherence may be even larger than to medication. We realise that both the definition of adherence and most of the literature deal with non-adherence to medication, and thus will not entirely apply to exercises or to other prescribed treatments, such as use of splints. However, due to the generic nature of the PtCs, we assume that our results can equally be applied to any treatment the patient is receiving and thus will cover exercises as well.

Two aspects differ from the initial plans of this taskforce. First, prevention was not initially included as an objective of the taskforce; however, it soon became clear that prevention is the ultimate solution to avoid non-adherence, and strategies to achieve it will probably overlap with those of an optimal SDM process. Second, in the proposal approved by the EULAR executive, non-adherence to visits and to diet, and not only to medication or exercises, were initially included. However, the taskforce thought that visits and diet were too complex to measure, and would overlap with other initiatives, and left them out of the scope and the research agenda.

Finally, regarding the implementation of these PtCs, the taskforce wanted to stress, on one hand the need to adopt a truly patient-centred approach and, on the other, the need to make system changes. Several PtCs involve the patient as main stakeholder in the issue of non-adherence. Nothing can be done in terms of non-adherence without the help of the one who agrees, or not, to follow the treatment or exercises as prescribed. To engage him or her, we will need to attain basic effective communication skills and make SDM a reality. The consequences will be a better outcome and higher odds of adequate self-management.
Similarly, if we do not evaluate periodically non-adherence at an organisational level, and address system barriers, many of which are modifiable, including improved staff training, we will not be able to make effective changes, or measure the impact of implemented strategies. There is enough information to support better use of existing resources and treatments, this include reducing non-adherence.

In summary, these PtCs can help HCPs to support people with RMDs to adhere to the agreed treatment plan, the basic scheme being minimise non-adherence by bonding with the patient and building trust, and by overcoming structural barriers, assess in a blame-free environment and tailor the solution to the problem.

**Author affiliations**
1Section for Outcomes Research, Medical University of Vienna, Wien, Austria 2Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Wien, Austria 3Department of Rheumatology, Medical University of Vienna, Wien, Austria 4Rheumatology, UMC Utrecht, Utrecht, The Netherlands 5Deutsche Rheuma-Liga Bundesverband e.V., Bonn, Germany 6Rheumatology, Physical Medicine and Rheumatology, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania 7Department of Nursing and Midwifery, University of the West of England, Bristol, UK 8Academic Rheumatology, Bristol Royal Infirmary, Bristol, UK 9Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC University Medical Center, Rotterdam, The Netherlands 10Institut Pierre Louis d’Épidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France 11APRh, Rheumatology Department, Hospital Universitari Pitié Salpêtrière, Paris, France 12Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino, Italy 13Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Health Sciences Research Unit: Nursing, Coimbra, Portugal 14Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway 15Miftakim Tz’elit, Haifa, Israel 16Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands 17Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands 18Hospital Pharmacy, Diakonhjemmet Hospital, Oslo, Norway 19School of Pharmacy, University of Oslo, Oslo, Norway 20Department Psychology, Health and Technology, University of Twente, Enschede, The Netherlands 21Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark 22Department of Clinical Medicine, Aarhus University, Aarhus, Denmark 23Instituto de Salud Musculoesquelética (INMUSC), Madrid, Spain

**Twitter** Fernando Estévez-López @FernEstevzLopez1 and Loreto Carmona @carmona_loreto

**Acknowledgements** We thank Conni Krubbeltrang (Chief Librarian at Aalborg Universitetshospital) and José Bernado Negro-Troncoso (Instituto de Investigación Social y Sanitaria, Puerto Rico) for their contribution to the systematic literature search.

**Contributors** All listed authors of the manuscript are the members of the EULAR assigned task force dedicated to the development of points to consider for adherence to treatment in people with rheumatic and musculoskeletal diseases. All authors contributed to the formulation of the points to consider. In details, the steering committee of the task force (LC, VR and AdT) defined the research questions for the systematic literature searches. The search was performed by a research librarian (CS), under supervision of the methodologist (AdT). JBNT, AdT and LC selected the studies, VR assessed risk of bias of all eligible studies, VR, LC and JBNT extracted the data, and synthesised the results. LC and AdT reviewed processes, excluded articles and tailored the synthesis reports. The manuscript was drafted by VR and revised by LC, AdT and LC. All other authors participated in the taskforce meetings, suggested and agreed upon the research questions, read the report prior to the manuscript, discussed results and made contributions to the text. All authors approved the final version of the manuscript.

**Funding** This project was funded by EULAR (project number HP037).

**Competing interests** TAS has received grant/research support from AbbVie, and Roche, and has been consultant for AbbVie, Sanofi Genzyme, and has been paid speaker for MSF, AbbVie, Novartis, Roche, Pfizer, Mylan and Sandoz. ED has received grant/research support from Independent Learning, Pfizer, combined funding for a research fellow from Celgene, Abbvie and Novartis, and has been paid instructor for Novartis to deliver training to nurses. LG has received grant/research support from Lilly, Pfizer and Sandoz, and has been consultant for AbbVie, Amscan, Biogen, IMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi, Sandoz, Sanofi-Aventis and UCB Pharma. BJvdB has been paid speaker for MSD, Abbvie and Biogen. MV has been paid speaker for Pfizer. AdT has received grants from Novartis, and has been paid speaker for Lilly and Pfizer. LC has received grant/research support through her institute from Novartis, Pfizer, MSD, Roche, Sanofi Aventis, AbbVie and Gebro Pharma.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omisions arising from translation and adaptation or otherwise.

**ORCID iDs**
- Valentin Ritschl http://orcid.org/0000-0001-8763-8215
- Tanja A Stamm http://orcid.org/0000-0003-3073-7284
- Daniel Aletaha http://orcid.org/0000-0003-2108-0030
- Johannes W J Bijlsma http://orcid.org/0000-0002-1218-8451
- Peter Böhm http://orcid.org/0000-0002-6764-8607
- Fernando Estévez-López http://orcid.org/0000-0003-2960-4142
- Laure Gossec http://orcid.org/0000-0002-4528-310X
- Annamaria Iagnocco http://orcid.org/0000-0001-5592-724X
- Andrea Marques http://orcid.org/0000-0002-2026-9926
- Bart J F van den Bemt http://orcid.org/0000-0002-8560-9514
- Kirsten Vikli http://orcid.org/0000-0003-2361-5107
- Mariëke Voshaar http://orcid.org/0000-0002-4161-0126
- Annette de Thurah http://orcid.org/0000-0003-0103-4328
- Loreto Carmona http://orcid.org/0000-0002-4401-2551

**REFERENCES**


22 Centre for Evidence-Based Medicine. OCEBM levels of evidence, 2016. Available: https://www.cebm.net/2016/05/cebms-levels-of-evidence/


